2,3-bis(benzoyloxy)tartaric acid: SNC-86 refers to (-)dibenzoyl-L-tartaric acid salt [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 75969 |
| CHEMBL ID | 1464055 |
| SCHEMBL ID | 221678 |
| MeSH ID | M0399133 |
| Synonym |
|---|
| 3-09-00-00870 (beilstein handbook reference) |
| nsc 338494 |
| unii-3q14b666vm |
| ec 220-374-0 |
| 3q14b666vm , |
| 2743-38-6 |
| dibenzoyl-l-tartaric acid |
| NCGC00091026-01 |
| dibenzoyl-l-tartaric acid, 98% |
| D1354 |
| 2,3-bis(benzoyloxy)tartaric acid |
| dibenzoyltartaric acid |
| tartaric acid, dibenzoate, (-)- |
| butanedioic acid, 2,3-bis(benzoyloxy)-, (2r,3r)- |
| (-)-dibenzoyl tartaric acid |
| brn 0709854 |
| nsc 118224 |
| butanedioic acid, 2,3-bis(benzoyloxy)-, (r-(r*,r*))- |
| 2,3-bis(benzoyloxy)-butanedioic acid, (r-(r*,r*))- |
| tartaric acid, dibenzoate |
| einecs 220-374-0 |
| (2r,3r)-2,3-bis(benzoyloxy)succinic acid |
| smr001227193 |
| MLS001055407 |
| AC-3430 |
| D3492 |
| AKOS000277983 |
| (-)-dibenzoyl-l-tartaric acid |
| 62708-56-9 |
| NCGC00091026-02 |
| l-dibenzoyl tartaric acid |
| HMS3039M05 |
| NCGC00258772-01 |
| cas-2743-38-6 |
| dtxsid6033401 , |
| dtxcid4013401 |
| tox21_201220 |
| l(-)-o,o'-dibenzoyl-tartaric acid |
| (-)-2,3-dibenzoyl-l-tartaric acid |
| (-)-o,o'-dibenzoyl-l-tartaric acid |
| (2r,3r)-2,3-bis(benzoyloxy)butanedioic acid |
| dibenzoyltartric acid |
| (-)-l-dibenzoyltartaric acid |
| (-)-o,o'-dibenzoyltartaric acid |
| (2r,3r)-di-o-benzoyltartaric acid |
| ramipril impurity m [ep impurity] |
| SCHEMBL221678 |
| CHEMBL1464055 |
| AM81406 |
| (-)-dibenzoyl-l-tartaric acid, anhydrous |
| J-500963 |
| (2r,3r)-(-)-dibenzoyl-l-tartaric acid anhydrous |
| mfcd00003074 |
| (2r,3r)-2,3-bis(benzoyloxy)butanedioic acid; ramipril imp. m (ep); dibenzoyltartric acid; ramipril impurity m |
| dibenzoyl-(+)-tartaric acid |
| CS-D1145 |
| l-(-)-0,0'-dibenzoyl tartaric acid |
| l-(-)-o,o'-dibenzoyl tartaric acid |
| YONLFQNRGZXBBF-ZIAGYGMSSA-N |
| AS-10935 |
| Q27257884 |
| EN300-137519 |
| Z1688267840 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Due to low central nervous system (CNS) bioavailability of delta-opioid peptides, little is known about the effect of systemic administration of delta-opioid receptor ligands." | ( Spinal delta-opioid receptors mediate suppression of systemic SNC80 on excitability of the flexor reflex in normal and inflamed rat. Cao, CQ; Dray, A; Hong, Y; Perkins, M, 2001) | 0.31 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 79.4328 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 1.1577 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 7.0795 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 7.9433 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 26.2420 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 1.5605 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 5.5370 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 1.1146 | 0.0010 | 24.5048 | 61.6448 | AID743212 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 69.7072 | 0.0007 | 23.0674 | 1,258.9301 | AID743085 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 0.0079 | 0.3162 | 12.4435 | 31.6228 | AID924 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 74.9780 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| geminin | Homo sapiens (human) | Potency | 0.1369 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 5.5370 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 0.0079 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 0.0079 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 5.5370 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.60) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||